0001567619-20-013187.txt : 20200710
0001567619-20-013187.hdr.sgml : 20200710
20200710185516
ACCESSION NUMBER: 0001567619-20-013187
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200710
FILED AS OF DATE: 20200710
DATE AS OF CHANGE: 20200710
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rice William G.
CENTRAL INDEX KEY: 0001761487
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32001
FILM NUMBER: 201024073
MAIL ADDRESS:
STREET 1: C/O APTOSE BIOSCIENCES INC.
STREET 2: 251 CONSUMERS ROAD, SUITE 1105
CITY: TORONTO
STATE: A6
ZIP: M2J 4R3
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aptose Biosciences Inc.
CENTRAL INDEX KEY: 0000882361
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A6
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 251 CONSUMERS ROAD
STREET 2: SUITE 1105
CITY: TORONTO
STATE: A6
ZIP: M2J 4R3
BUSINESS PHONE: 647-479-9828
MAIL ADDRESS:
STREET 1: 251 CONSUMERS ROAD
STREET 2: SUITE 1105
CITY: TORONTO
STATE: A6
ZIP: M2J 4R3
FORMER COMPANY:
FORMER CONFORMED NAME: Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.)
DATE OF NAME CHANGE: 20140905
FORMER COMPANY:
FORMER CONFORMED NAME: LORUS THERAPEUTICS INC
DATE OF NAME CHANGE: 19990308
FORMER COMPANY:
FORMER CONFORMED NAME: IMUTEC PHARMA INC
DATE OF NAME CHANGE: 19970113
4
1
doc1.xml
FORM 4
X0306
4
2020-07-10
0
0000882361
Aptose Biosciences Inc.
APTO
0001761487
Rice William G.
C/O APTOSE BIOSCIENCES INC.
251 CONSUMERS ROAD, SUITE 1105
TORONTO
A6
M2J 4R3
ONTARIO, CANADA
1
1
0
0
Chair, President & CEO
Common Shares
2020-07-10
4
S
0
168891
6.05
D
297523
D
The reporting person's sale of APTO common stock reported herein (see footnote 2 below) was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 3,400 shares, with the reporting person's purchase of 3,400 shares of APTO common stock at a price of $5.8244 per share on March 25, 2020. The reporting person has agreed to pay to Aptose Biosciences Inc., upon settlement of the sale, $767.04, representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs.
Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of 300,000 restricted stock units, previously reported on a Form 4/A filed with the Securities and Exchange Commission on March 10, 2020.
/s/ Janet Clennett as attorney-in-fact for William G. Rice
2020-07-10